Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Leukotriene B4 and Polyunsaturated Fatty Acids

Research Papers that Mention the Interaction

However, n-3 PUFA supplementation significantly decreased NSAID requirements and leukotriene B4 levels in patients who weighed more than 55 kg.
The Journal of nutritional biochemistry  •  2013  |  View Paper
Accordingly, LTB4 levels were inversely related to membrane n-3 PUFA levels.
Clinical science  •  2007  |  View Paper
Dietary supplementation with n-3 PUFA also resulted in augmentation of depressed neutrophil chemotaxis to LTB4 and FMLP.
The Proceedings of the Nutrition Society  •  1998  |  View Paper
COX-2 expression (P<.05) and pro-inflammatory eicosanoids production of prostaglandin E2 (P<.001) and leukotriene B4 (P<.001) were significantly inhibited by n-3 PUFA or 5-ASA therapy.
The Journal of nutritional biochemistry  •  2013  |  View Paper
Dietary fortification of n-9 polyunsaturated fatty acids (PUFA) or 5,8,11-eicosatrienoic acid (ETrA) as well as n-3 PUFA might contribute to the suppression of leukotriene B4 (LTB4) synthesis and thereby reduce inflammatory bowel lesions.
Surgery Today  •  2003  |  View Paper
On the other hand, LTB4 release from rat peritoneal exudate cells was inhibited in the presence of polyunsaturated fatty acids , both n-6 and n-3, having more than 3 double bonds.
These results suggest that lipophilic anti-oxidative agents, as well as PUFA , inhibit the production of LTB4.
Journal of nutritional science and vitaminology  •  1996  |  View Paper